Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Market: Market:

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology GlobeNewswire - Wed Oct 16, 7:30AM CDT
CMTX - Wed Oct 16, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research...

ATOS : 1.78 (+0.56%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia ACCESSWIRE - Tue Oct 15, 11:49AM CDT
CMTX - Tue Oct 15, 11:49AM CDT

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.78 (+0.56%)
JNJ : 127.70 (-6.22%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia ACCESSWIRE - Tue Oct 15, 11:47AM CDT
CMTX - Tue Oct 15, 11:47AM CDT

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.78 (+0.56%)
JNJ : 127.70 (-6.22%)
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen GlobeNewswire - Mon Sep 30, 7:30AM CDT
CMTX - Mon Sep 30, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary...

ATOS : 1.78 (+0.56%)
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference GlobeNewswire - Fri Sep 6, 8:56AM CDT
CMTX - Fri Sep 6, 8:56AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.78 (+0.56%)
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet GlobeNewswire - Tue Sep 3, 7:01AM CDT
CMTX - Tue Sep 3, 7:01AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all...

ATOS : 1.78 (+0.56%)
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update GlobeNewswire - Tue Aug 13, 12:26PM CDT
CMTX - Tue Aug 13, 12:26PM CDT

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.78 (+0.56%)
Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk GlobeNewswire - Tue Jul 30, 7:30AM CDT
CMTX - Tue Jul 30, 7:30AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online...

ATOS : 1.78 (+0.56%)
Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests GlobeNewswire - Wed Jul 17, 7:30AM CDT
CMTX - Wed Jul 17, 7:30AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported that patients...

ATOS : 1.78 (+0.56%)
Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated GlobeNewswire - Thu Jul 11, 7:30AM CDT
CMTX - Thu Jul 11, 7:30AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it...

ATOS : 1.78 (+0.56%)
Thinking about buying stock in Aileron Therapeutics, Atossa Genetics, NVIDIA, Seelos Therapeutics, or Xpresspa? PR Newswire - Thu Jun 27, 8:31AM CDT
CMTX - Thu Jun 27, 8:31AM CDT

InvestorsObserver issues critical PriceWatch Alerts for ALRN, ATOS, NVDA, SEEL, and XSPA.

ALRN : 0.42 (+1.28%)
ATOS : 1.78 (+0.56%)
NVDA : 190.49 (-1.96%)
XSPA : 1.43 (+16.26%)
Atossa Genetics' Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density GlobeNewswire - Thu Jun 27, 7:00AM CDT
CMTX - Thu Jun 27, 7:00AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary...

ATOS : 1.78 (+0.56%)
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire - Tue May 14, 4:42AM CDT
CMTX - Tue May 14, 4:42AM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.78 (+0.56%)
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit GlobeNewswire - Thu Apr 25, 11:00AM CDT
CMTX - Thu Apr 25, 11:00AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven...

ATOS : 1.78 (+0.56%)
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.? PR Newswire - Wed Apr 24, 8:31AM CDT
CMTX - Wed Apr 24, 8:31AM CDT

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ.

AKTX : 1.69 (-2.87%)
ATOS : 1.78 (+0.56%)
ACBFF : 8.6900 (-12.80%)
BA : 344.00 (-6.79%)
Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019 GlobeNewswire - Mon Apr 22, 7:30AM CDT
CMTX - Mon Apr 22, 7:30AM CDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Steven...

ATOS : 1.78 (+0.56%)
New Research Coverage Highlights Thermon Group, Apogee Enterprises, National Research, Gulf Resources, Atossa Genetics, and Broadwind Energy -- Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire - Thu Apr 18, 6:40AM CDT
CMTX - Thu Apr 18, 6:40AM CDT

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Thermon Group Holdings, Inc....

NRCIA : 33.55 (+1.51%)
THR : 23.03 (-0.04%)
APOG : 37.25 (-0.19%)
NRC : 57.08 (+1.93%)
GURE : 0.66 (-5.05%)
ATOS : 1.78 (+0.56%)
BWEN : 1.61 (+2.55%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options CNW Group - Thu Apr 11, 8:00AM CDT
CMTX - Thu Apr 11, 8:00AM CDT

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
ATOS : 1.78 (+0.56%)
AGEN : 2.62 (-2.24%)
SNSS : 0.57 (-2.25%)
OMED : 0.93 (+4.49%)
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update GlobeNewswire - Thu Mar 28, 3:29PM CDT
CMTX - Thu Mar 28, 3:29PM CDT

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced year...

ATOS : 1.78 (+0.56%)
Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient GlobeNewswire - Tue Mar 26, 7:29AM CDT
CMTX - Tue Mar 26, 7:29AM CDT

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that...

ATOS : 1.78 (+0.56%)
Please wait...

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
Mon Aug 19, 3:14PM CDT
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
See More
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot